Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
58%(7 trials)

Phase Distribution

Ph phase_3
9
75%
Ph phase_4
2
17%
Ph phase_2
1
8%

Phase Distribution

0

Early Stage

1

Mid Stage

11

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
9(75.0%)
Phase 4Post-market surveillance
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(12)

Detailed Status

Completed12

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (8.3%)
Phase 39 (75.0%)
Phase 42 (16.7%)

Trials by Status

completed12100%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

NCT00929331
completedphase_4

A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk

NCT00586469
completedphase_3

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

NCT00718120
completedphase_3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults

NCT01626820
completedphase_3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

NCT01878825
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00929331Phase 3

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

Completed
NCT00586469Phase 4

A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk

Completed
NCT00718120Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years

Completed
NCT01626820Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults

Completed
NCT01878825Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

Completed
NCT01153685Phase 3

Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years

Completed
NCT01389479Phase 3

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

Completed
NCT00764998Phase 3

Influenza Vaccine in HIV

Completed
NCT02560909Phase 4

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Completed
NCT00505453Phase 3

A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine

Completed
NCT00784784Phase 3

Zanamivir Versus Trivalent Split Virus Influenza Vaccine

Completed
NCT01180621Phase 2

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Completed

All 12 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
12